Completed OBSERVATIONAL NCT05100368

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Sponsor: Istituto Ortopedico Rizzoli

Interventions patients

Updated 8 times since 2021 Last updated: Jul 19, 2023 Started: Apr 2, 2021 Primary completion: Jul 1, 2021 Completion: Jul 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05100368, this observational or N/A phase trial focuses on Sarcoma, Ewing and remains completed. Sponsored by Istituto Ortopedico Rizzoli, it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Aug 2023 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Jun 2023 — Aug 2023 [monthly]

Active Not Recruiting
Apr 2023 — Jun 2023 [monthly]

Active Not Recruiting

▶ Show 3 earlier versions

May 2022 — Apr 2023 [monthly]

Active Not Recruiting
Apr 2022 — May 2022 [monthly]

Active Not Recruiting
Nov 2021 — Apr 2022 [monthly]

Active Not Recruiting

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto Ortopedico Rizzoli

Data source: Istituto Ortopedico Rizzoli

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bologna, Italy